Product Description
Brivaracetam is used alone and in combination with other medications to control partial onset seizures (seizures that involve only one part of the brain) in adults, children, and infants 1 month of age and older. Brivaracetam is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in the brain. (Sourced from: https://medlineplus.gov/druginfo/meds/a616027.html)
Mechanisms of Action: SV2A Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Mexico | Netherlands | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States
Approved Indications: Seizures
Known Adverse Events: Dizziness
Company: UCB
Company Location: SMYRNA GA 30080
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, China, Czech Republic, France, Georgia, Germany, Hungary, Ireland, Italy, Japan, Malaysia, Mexico, Philippines, Poland, Romania, Singapore, Slovakia, Spain, Taiwan, Thailand, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 22
Highest Development Phases
Phase 3: Epilepsy|Epilepsy, Absence|Epilepsy, Generalized|Myoclonic Epilepsy, Juvenile|Seizures
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| EP0224 | P3 |
Recruiting |
Myoclonic Epilepsy, Juvenile|Epilepsy, Absence |
2030-03-01 |
|
| EP0156 | P3 |
Active, not recruiting |
Epilepsy |
2029-07-17 |
|
| EP0224 | P3 |
Unknown Status |
Epilepsy, Absence|Myoclonic Epilepsy, Juvenile |
2029-02-28 |
|
| 2014-004397-42 | P3 |
Active, not recruiting |
Epilepsy |
2028-02-15 |